Alcoh Development

Alcoh is a clinical-stage biopharmaceutical company focused on the development of novel pharmacological treatments for Alcohol Use Disorder (AUD). The company's lead program, AD-101, is a proprietary fixed-dose combination of the opioid antagonist naltrexone and the tricyclic antidepressant amitriptyline. This combination is designed to synergistically target the neurobiological pathways involved in alcohol craving and the emotional distress associated with withdrawal. Alcoh's approach aims to improve patient adherence and clinical outcomes compared to existing monotherapies. The company is currently conducting Phase 2 clinical studies to evaluate the efficacy of AD-101 in reducing heavy drinking days and maintaining abstinence.